Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).
Christopher B. Fox
Advertisement
Christopher B. Fox is the lead formulation engineer at the Infections Disease Research Institute
Articles by Christopher B. Fox
Advertisement
Latest Updated Articles
Characterization of Aluminum Hydroxide Gel and Oil-in-Water Emulsion Formulations Containing CpG ODNsPublished: October 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
2
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
3
Q&A: Strategies for Supply Chain Resilience and Next-Generation Process Optimization
4
BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints
5
